logo
  • Alembic Global
  • Corporate Video
  • Contact Us
  • image
  • About Us About Us
    Back

    About Us

    We are a vertically integrated pharmaceutical company committed to delivering
    high-quality healthcare for patients around the world.

    Read more
    • Corporate Profile
    • Journey
    • Leadership
    • Subsidiaries, Associates & JVs
    • Accolades
    • D&B Report & Certificates
    image

    Accelerating access to quality medicines

  • Business Business
    Back

    Business

    We work to identify new and existing gaps, and strengthen healthcare and life science by addressing them.

    Read more
    • India Formulations
    • International Generics
    • Active Pharmaceutical Ingredients
    image

    Addressing unmet and evolving patient needs

  • Capabilities Capabilities
    Back

    Capabilities

    We are enhancing our capacities to develop high-quality, differentiated solutions to ensure good health and well-being for people everywhere.

    Read more
    • Manufacturing
    • Research and Development
    • Quality and Compliance
    image

    Creating benchmarks in innovation

  • Investors Investors
    Back

    Investors

    We believe that our strengths lie in leveraging them appropriately to deliver long-term, sustainable value to our customers and shareholders.

    Read more
    • Financial Information
      Back
      • Quarterly Results
      • Investor Presentations
      • Annual Reports
      • Business Update
    • Corporate Governance
      Back
      • Governance Philosophy
      • Board of Directors
      • Composition of the Committees
      • Policies & Codes
    • Corporate Social Responsibility
    • Shareholder Information
      Back
      • Shareholding Pattern
      • Notices/Correspondences/Disclosures
      • IEPF
      • Unpaid/Unclaimed Dividend
      • QIP
      • MOA & AOA
      • Familiarization Programme
      • Annual Return
      • Scheme of Arrangement Aleor & APL
      • Scheme of Arrangement Reorganization of General Reserves
    • Subsidiaries, Associates & JV's
    • Investor Relations
    • Investor Related Forms
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations
    • Disclosure under Regulation 62 of SEBI (LODR) Regulations
    image

    Delivering sustained returns

  • Responsibility Responsibility
    Back

    Responsibility

    Working with an unflinching sense of duty towards the communities where our operations thrive and the planet at large.

    Read more
    • Education
    • Health
    • Community
    image

    Touching lives in myriad ways

  • Careers Careers
    Back

    Careers

    Seeking innovative minds who aspire to broaden the horizons of quality healthcare and connecting them with growth opportunities are our top priorities as responsible employers.

    Read more
    • Life at Alembic
    • Opportunities
    image

    Developing path-breaking solutions

  • Media Media
    Back

    Media

    Our latest press releases and announcements.

    Read more
    • Press Releases
    • News & Insights
    • Alembic Gallery
    image

    Setting the trend

  • Reporting side effect
  • Contact Us
Press Releases

Stay updated on the latest in Alembic

  1. Media
  2. Press Releases
  • 2022-2023
  • 2021-2022
  • 2020-2021
  • 2019-2020
  • 2018-2019
  • 2017-2018
  • 2016-2017
  • 2015-2016
  • 2014-2015
  • 2013-2014
  • 2012-2013
  • 2011-2012
  • 2010-2011
  • Completion Of USFDA Inspection Derma Facility At Karakhadi 13th March, 2023

    March, 2023
  • Press Release USFDA Tentative Approval for Brexpiprazole Tablets, March, 2023

    March, 2023
  • Press Release USFDA Final Approval Prazosin Hydrochloride Capsules USP, March, 2023

    March, 2023
  • Press Release USFDA Final Approval Fluorouracil Injection USP, March, 2023

    March, 2023
  • Press Release USFDA Final Approval Docetaxel Injection USP, March, 2023

    March, 2023
  • Press Release December, 2022

    February, 2023
  • Press Release USFDA Tentative Approval Acalabrutinib Capsules, 100 Mg, January, 2023

    January, 2023
  • Press Release USFDA Final Approval Fesoterodine Fumarate Extended-Release Tablets, 4 Mg and 8 Mg, January, 2023

    January, 2023
  • Press Release USFDA Final Approval Fulvestrant Injection, 250 Mg-5 Ml, December, 2022

    December, 2022
  • Press Release PAS Approval USFDA Pregabalin Capsules, December, 2022

    December, 2022
  • Press Release USFDA Final Approval Desonide Cream, 0.05%, December, 2022

    December, 2022
  • Press Release USFDA Final Approval Diclofenac Sodium Topical Solution USP, 2% ww, December, 2022

    December, 2022
  • Press Release USFDA Final Approval Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg And 90 Mg, November, 2022

    November, 2022
  • Press Release USFDA Final Approval Cyclophosphamide Capsules, 25 Mg And 50 Mg, November, 2022

    November, 2022
  • Press Release September, 2022

    November, 2022
  • Press Release USFDA Final Approval Ketorolac Tromethamine Injection USP, November, 2022

    November, 2022
  • Press Release USFDA Final Approval Mesalamine Extended-Release Capsules USP, 0.375 g, November, 2022

    November, 2022
  • Press Release USFDA Final Approval Glycopyrrolate Injection USP, November, 2022

    November, 2022
  • Press Release USFDA Final Approval Paclitaxel Injection USP, October, 2022

    October, 2022
  • Press Release USFDA Final Approval Chlorthalidone Tablets USP, 25 Mg And 50 Mg August, 2022

    August, 2022
  • Press Release Aleor USFDA Final Approval Adapalene And Benzoyl Peroxide Topical Gel, 0.3% 2.5%, August, 2022

    August, 2022
  • Press Release June, 2022

    August, 2022
  • Press Release Aleor USFDA Final Approval Diclofenac Sodium Topical Gel, 3%, July, 2022

    July, 2022
  • Press Release USFDA Tentative Approval Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, & 140 Mg. June, 2022

    June, 2022
  • Press Release USFDA Final Approval Pirfenidone Tablets, 267 Mg And 801 Mg May, 2022

    May, 2022
  • Press Release USFDA Final Approval Arformoterol Tartrate Inhalation Solution,15 MCG (base) 2ML Unit-dose Vial May, 2022

    May, 2022
  • Press Release Aleor USFDA Final Approval Docosanol Cream, 10% (OTC), May, 2022

    May, 2022
  • Press Release Aleor USFDA Final Approval Clobetasol Propionate Foam, 0.05%, April, 2022

    April, 2022
  • Press Release March, 2022

    May, 2022
  • Press Release USFDA Tentative Approval Ivabradine Tablets, 5 Mg And 7.5 Mg. April, 2022

    May, 2022
  • Press Release Aleor USFDA Final Approval Lidocaine And Prilocaine Cream USP, 2.5%/2.5%, April, 2022

    April, 2022
  • Press Release USFDA Tentative Approval Dabigatran Etexilate Capsules, 75 Mg, 110 Mg, And 150 Mg. April, 2022

    April, 2022
  • Press Release USFDA Final Approval Lacosamide Tablets USP, 50 MG, 100 MG, 150MG And 200 MG.

    March, 2022
  • Press Release USFDA Tentative Approval Macitentan Tablets, 10 MG.

    March, 2022
  • Press Release Aleor USFDA Final Approval Nystatin And Triamcinolone Acetonide Ointment USP, 100,000 Units/Gram

    March, 2022
  • Press Release

    December, 2021
  • Press Release USFDA Tentative Approval Fesoterodine Fumarate Extended-Release Tablets, 4 MG And 8 MG.

    February, 2022
  • Press Release USFDA Final Approval Clarithromycin Tablets USP, 250 MG And 500 MG

    February, 2022
  • Press Release USFDA Tentative Approval Dronedarone Tablets USP, 400 mg.

    January, 2022
  • Press Release USFDA Tentative Approval Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg.

    January, 2022
  • Press Release USFDA Final Approval Entacapone Tablets USP, 200 mg.

    January, 2022
  • Press Release USFDA Final Approval Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg.

    January, 2022
  • Press Release Acquisition Preferred Stock of RIGImmune, Inc,

    December, 2021
  • Press Release USFDA Tentative Approval Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg.

    December, 2021
  • Press Release USFDA Tentative Approval Dabigatran Etexilate Capsules, 150 mg.

    November, 2021
  • Press Release USFDA Final Approval Formoterol Fumarate Inhalation Solution, 20 mcg/2 ml per Unit-Dose Vial.

    November, 2021
  • Press Release Aleor USFDA Final Approval Mupirocin Cream USP, 2%.

    November, 2021
  • Press Release

    September, 2021
  • Press Release Aleor USFDA Final Approval Metronidazole Gel USP. 1%.

    September, 2021
  • Press Release USFDA Final Approval Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg.

    August, 2021
  • Press Release USFDA Final Approval Erlotinib Tablets, 25 mg, 100 mg, and 150 mg.

    July, 2021
  • Press Release USFDA Final Approval Desipramine Hydrochloride Tablets USP, 10 mg. 25 mg. 50 mg, 75 mg, 100 mg, and 150 mg.

    July, 2021
  • Press Release USFDA Final Approval Nitrofurantoin Capsules USP (Macrocrystals), 25 mg, 50 mg and 100 mg.

    July, 2021
  • Press Release

    June, 2021
  • Press Release Aleor USFDA Final Approval Testosterone Topical Solution USP, 30 mg per pump actuation.

    June, 2021
  • Press Release USFDA Final Approval Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg.

    May, 2021
  • Press Release USFDA Final Approval Dorzolamide Hydrochloride & Timolol Maleate Ophthalmic Solution USP, 2% and 0.5%

    May, 2021
  • Press Release Aleor USFDA Tentative Approval for Metronidazole Gel USP, 1%

    May, 2021
  • Press Release USFDA Final Approval Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg

    April, 2021
  • Press Release Aleor USFDA Tentative Approval for Efinaconazole Topical Solution, 10%

    April, 2021
  • Press Release Aleor USFDA Final Approval Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram.

    April, 2021
  • Press Release

    March, 2021
  • Press Release Aleor USFDA Final Approval Testosterone Gel, 1.62%

    March, 2021
  • Press Release AGH USFDA Final Approval Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), Multiple-Dose Vials.

    February, 2021
  • Press Release - Rhizen - Umbralisib-UNKONIQ Approval

    February, 2021
  • Press Release USFDA Final Approval Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, & 10 mg.

    January, 2021
  • Press Release

    December, 2020
  • Press Release USFDA Final Approval Asenapine Sublingual Tablets, 5 mg & 10 mg

    December, 2020
  • Press Release USFDA Final Approval Metolazone Tablets USP 2.5 mg, 5 mg & 10 mg

    December, 2020
  • Press Release Rhizen USFDA Acceptance IND Application SARS-CoV-2 Infection

    December, 2020
  • Press Release Aleor USFDA Tentative Approval Testosterone Gel, 1.62%

    November, 2020
  • Press Release USFDA Tentative Approval Palbociclib Capsules, 75 mg, 100 mg, and 125 mg

    November, 2020
  • Press Release Aleor USFDA Final Approval Tavaborole Topical Solution, 5%

    October, 2020
  • Press Release USFDA Approval Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg

    October, 2020
  • Press Release USFDA Approval Amantadine Hydrochloride Tablets, 100 mg

    October, 2020
  • Press Release Rhizen ELA Tenalisib

    October, 2020
  • Press Release

    September, 2020
  • Press Release USFDA Tentative Approval Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), Multiple-Dose Vials.

    September, 2020
  • Press Release USFDA Tentative Approval Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg.

    August, 2020
  • Press Release Aleor USFDA Final Approval Desonide Lotion, 0.05%

    August, 2020
  • Press Release Aleor USFDA Tentative Approval for Tavaborole Topical Solution, 5%

    August, 2020
  • Press Release USFDA Approval Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base)

    August, 2020
  • Press Release USFDA Tentative Approval Empagliflozin Metformin Hydrochloride Tablets, 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg.

    July, 2020
  • Press Release USFDA Approval Doxycycline Hyclate Tablets USP 75 mg & 150 mg

    July, 2020
  • Press Release USFDA Tentative Approval Rivaroxaban Tablets, 10 mg, 15 mg, and 20 mg.

    June, 2020
  • Press Release

    June, 2020
  • Press Release Aleor USFDA Final Approval Adapalene Gel USP, 0.3

    June, 2020
  • Press Release USFDA Approval Deferasirox Tablets 180 mg

    June, 2020
  • Press Release Aleor USFDA Approval Clobetasol Propionate Shampoo, 0.05%

    May, 2020
  • Press Release USFDA Approval Doxycycline Hyclate Tablets USP 100 mg

    May, 2020
  • Press Release USFDA Tentative Approval for Alcaftadine Ophthalmic Solution, 0.25%.

    April, 2020
  • Press Release COVID 19 Pandemic

    April, 2020
  • Press Release

    March, 2020
  • Press Release USFDA Approval Doxycycline Hyclate Tablets USP 20 mg

    March, 2020
  • Press Release Aleor USFDA Approval Clobetasol Propionate Cream, 0.05%

    January, 2020
  • Press Release USFDA Approval Azithromycin Tablets USP 250 mg & 500 mg

    January, 2020
  • Press Release USFDA Approval Azithromycin Tablets USP, 600 mg.

    January, 2020
  • Press Release USFDA Approval Bosentan Tablets, 62.5 mg and 125 mg.

    January, 2020
  • Press Release USFDA Approval Vilazodone Hydrochloride Tablets, 10 mg, 20 mg, and 40 mg.

    January, 2020
  • Press Release USFDA Approval Travoprost Ophthalmic Solution USP, 0.004%

    December, 2019
  • Press Release Aleor USFDA Tentative Approval Diclofenac Sodium USP, 2% w/w.

    December, 2019
  • Press Release

    December, 2019
  • Press Release USFDA Approval Silodosin Capsules 4 mg and 8 mg

    November, 2019
  • Press Release USFDA Approvals Deferasirox Tablets

    November, 2019
  • Press Release Aleor USFDA Approval Desonide Ointment, 0.05%

    October, 2019
  • Press Release Aleor USFDA Approval Clobetasol Propionate Topical Solution, 0.05%

    October, 2019
  • Press Release Aleor USFDA Approval Clobetasol Propionate Spray, 0.05%

    October, 2019
  • Press Release

    September, 2019
  • USFDA Inspection at Bioequivalence Facility

    August, 2019
  • Press Release USFDA Approval Fenofibrate Tablets USP, 48 mg and 145 mg

    August, 2019
  • Press Release USFDA Approval Dorzolamide Hydrochloride Ophthalmic Solution USP, 2%.

    August, 2019
  • Press Release USFDA Tentative Approval Dapagliflozin Tablets, 5 mg and 10 mg.

    July, 2019
  • Press Release USFDA Approval Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.

    July, 2019
  • Press Release USFDA Approval Febuxostat Tablets, 40 mg and 80 mg.

    July, 2019
  • Press Release Clonazepam Orally Disintegrating Tablets USP, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg.

    July, 2019
  • Press Release Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base). June 2019

    June, 2019
  • Press Release

    June, 2019
  • Press Release USFDA Bromfenac Ophthalmic Solution 0.09%

    June, 2019
  • Press Release USFDA Approval Carbidopa Levodopa ER Tab USP, 25 mg/100 mg and 50 mg/200 mg.

    June, 2019
  • Press Release USFDA Approval Solifenacin Succinate Tablets, 5 mg and 10 mg.

    May, 2019
  • Press Release JVA Chinese Market

    May, 2019
  • Press Release USFDA Approval Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%.

    May, 2019
  • Press Release USFDA Approval Teriflunomide Tablets. 7 mg and 14 mg.

    April, 2019
  • Press Release USFDA Approval Tobramycin Ophthalmic Solution USP, 0.3%.

    April, 2019
  • Press Release USFDA Approval Bimatoprost Ophthalmic Solution, 0.03%

    April, 2019
  • Press Release

    March, 2019
  • Press Release USFDA Approval Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg.

    March, 2019
  • Press Release USFDA Approval Azelastine Hydrochloride Ophthalmic Solution, 0,05%

    March, 2019
  • Press Release Aleor USFDA Approval Clobetasol Propionate Ointment USP, 0.05%

    March, 2019
  • Press Release USFDA Approval Acetazolamide Extended-Release Capsules, 500 mg

    February, 2019
  • Press Release USFDA Approval Moxifloxacin Ophthalmic Solution USP 0.5%

    February, 2019
  • Press Release Orit USFDA Approval for Fenofibrate Tablets USP, 54 mg and 160 mg. February, 2019

    February, 2019
  • Press Release USFDA Approval Pramipexole Dihydrochloride Extended Release Tablets, 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, and 4.5 mg.

    January, 2019
  • Press Release

    December, 2018
  • USFDA Inspection API Facility at Panelav

    December, 2018
  • Press Release USFDA Approval Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%

    December, 2018
  • Press Release USFDA Approval Candesartan Cilexetil Tablets USP, 4 mg, 8 mg, and 16 mg.

    December, 2018
  • Press Release Orit USFDA Approval Glycopyrrolate Tablets USP, 1 mg and 2 mg.

    December, 2018
  • Press Release USFDA Approval Temazepam Capsules USP 7.5mg, 15mg, 22.5mg and 40mg.

    November, 2018
  • Press Release Aleor USFDA Approval Lidocaine Ointment USP, 5%

    November, 2018
  • Press Release USFDA Approval Vardenafil Hydrochloride Orally Disintegrating Tabletss, 10 mg.

    November, 2018
  • Press Release Successful USFDA Inspection at Aleor Dermaceuticals Limited

    October, 2018
  • Press Release USFDA Tentative Approval Alogliptin Tablets, 6.25 mg, 12.5 mg and 25 mg.

    October, 2018
  • Press Release

    September, 2018
  • Press Release USFDA Approval Desvenlafaxine Extended-Release Tablets, 25mg.

    September, 2018
  • Press Release USFDA Approval Desvenlafaxine Extended-Release Tablets, 25mg.

    September, 2018
  • Press Release USFDA Tentative Approval Alogliptin & Metformin Tablets, 12.5 mg/500 mg and 12.5 mg/1000 mg.

    September, 2018
  • Press Release USFDA Tentative Approval Bimatoprost Ophthalmic Solution, 0.03%

    August, 2018
  • Press Release USFDA Tentative Approval Ticagrelor Tablets 90mg

    July, 2018
  • Press Release USFDA Tentative Approval Iloperidone Tablets, 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg.

    July, 2018
  • Press Release

    June, 2018
  • Press Release USFDA Approval Doxycycline Hyclate Capsules USP, 50mg and 100mg

    June, 2018
  • Press Release USFDA Approval Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg

    June, 2018
  • USFDA Inspection API Facility at Karkhadi

    May, 2018
  • USFDA Inspection API Facility at Panelav

    April, 2018
  • Press Release USFDA Approval Acyclovir ointment USP, 5%

    April, 2018
  • Press Release

    March, 2018
  • USFDA Inspection Formulation Facility at Panelav

    March, 2018
  • Press Release

    December, 2017
  • Press Release Rhizen receives FDA Orphan-Drug Designation for Tenalisib (RP6530)

    December, 2017
  • Press Release USFDA Approval Darifenacin Extended Release Tablets, 7.5 mg and 15 mg.

    December, 2017
  • Press Release Rhizen receives FDA Fast Track Designation for RP6530 (tenalisib)

    December, 2017
  • Press Release Acquisition of US based generic drug developer Orit Laboratories LLC

    November, 2017
  • Press Release

    September, 2017
  • Press Release USFDA Approval Doxycycline Capsules USP, 75mg and 100mg.

    July, 2017
  • Press Release USFDA Approval Olmesartan Medoxomil & Amlodipine Tablets

    July, 2017
  • Press Release Inauguration Anti-Cancer Manufacturing Facility at Panelav, Halol

    July, 2017
  • Press Release USFDA Tentative Approval Dabigatran Etexilate Capsules, 150 mg.

    July, 2017
  • Press Release USFDA Tentative Approval Vardenafil Hydrochloride Orally Disintegrating Tablets

    July, 2017
  • Press Release

    June, 2017
  • Press Release USFDA Approval Amantadine Hydrochloride Capsules USP

    June, 2017
  • Press Release USFDA Approval Candesartan Cilexetil Tablets, 32 mg.

    June, 2017
  • Press Release USFDA Approval Fenofibric Acid Delayed-Release Capsules

    May, 2017
  • Press Release USFDA Approval Olmesartan Medoxomil Tablets & Olmesartan Medoxomil with Hydrochlorothiazide Tablets

  • Press Release USFDA Tentative Approval Vilazodone Tablets

    April, 2017
  • Press Release Successful USFDA Inspection Bioequivalence

    April, 2017
  • Press Release USFDA Approval Fluoxetine Hydrochloride Tablets

    April, 2017
  • Press Release

    March, 2017
  • Press Release Successful USFDA Inspection Bioequivalence

    March, 2017
  • Press Release Launch Desvenlafaxine Succinate Extended Release Tablets, 50 mg and 100 mg.

    March, 2017
  • Press Release

    December, 2016
  • Press Release USFDA Approval Itraconazole Capsules, 100 mg.

    December, 2016
  • Press Release Approval Telmisartan Amlodipine

    November, 2016
  • Press Release USFDA Approval Zolmitriptan Orally Disintergrating Tablets, 2.5 mg and 5 mg.

    November, 2016
  • Press Release

    September, 2016
  • Press Release USFDA Tentative Approval Febuxostat, 40 mg and 80 mg.

    July, 2016
  • Press Release

    June, 2016
  • Press Release - USFDA Approval - Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg.

    May, 2016
  • Press Release - JVA

    April, 2016
  • Press Release

    March, 2016
  • Press Release

    December, 2015
  • Press Release

    September, 2015
  • Press Release

    June, 2015
  • Press Release

    March, 2015
  • Press Release

    December, 2014
  • Press Release

    September, 2014
  • Press Release

    June, 2014
  • Press Release

    March, 2014
  • Press Release

    December, 2013
  • Press Release

    September, 2013
  • Press Release

    June, 2013
  • Press Release

    March, 2013
  • Press Release

    December, 2012
  • Press Release

    September, 2012
  • Press Release

    June, 2012
  • Press Release

    March, 2012
  • Press Release

    September, 2011
  • Press Release

    June, 2011
  • Press Release

    March, 2011

Explore more

About Us Business Capabilities Report an adverse event
footer logo

About us

Corporate Profile Journey Leadership Subsidiaries & Associates Accolades D&B Report & Certificates

Business

India Formulations International Generics Active Pharmaceutical Ingredients

Capabilities

Manufacturing Research and Development Quality and Compliance

Investors

Financial Information Corporate Governance Corporate Social Responsibility Shareholder Information Subsidiaries, Associates & JV's Investor Relations

Responsibility

Education Health Community

Careers

Life at Alembic Opportunities

Media

Press Releases News & Insights Alembic Gallery
  • Privacy Policy
  • Terms of Use
  • Disclaimer

Powered by D&C

© Alembic Pharmaceuticals Limited | Sitemap